IRIDEX Corporation Overview
Industry: Medical Devices
Sector: Healthcare
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glauc Read MoreMavefund brings filings, fundamentals, valuation, price history and news for IRIDEX Corporation into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $11.8M (-1% YoY). Net loss was -$0.5M. Adjusted EBITDA was $0.3M.
What changed
- Revenue -1% YoY to $11.8M.
Guidance / outlook
the Company expects to generate cash and for quarterly cash generation to improve sequentially.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Iridex expands EyeProGPO offering with EndoProbe handpieces
Headline from Investing.com: Iridex expands EyeProGPO offering with EndoProbe handpieces.
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
Headline from GlobeNewswire: Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering.
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
Headline from Yahoo Finance: Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering.
Portfolio Update 313 (NASDAQ:IRIX)
Headline from Seeking Alpha: Portfolio Update 313 (NASDAQ:IRIX).
Form 4 IRIDEX Corporation For: 14 July By Investing.com
Headline from Investing.com Nigeria: Form 4 IRIDEX Corporation For: 14 July By Investing.com.
Form 4 IRIDEX Corporation For: 14 July By Investing.com
Headline from Investing.com Canada: Form 4 IRIDEX Corporation For: 14 July By Investing.com.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.